Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of YL201 vs Irinotecan Liposome + 5‑FU/Calcium Folinate in Metastatic Pancreatic Ductal Adenocarcinoma After Gemcitabine Failure
CTR20263221Phase 3Active
- Sponsor
- MediLink Therapeutics
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of YL201 in pancreatic adenocarcinoma (PDAC), sponsored by MediLink Therapeutics. Started Sep 2026; status: active.
02
Drugs
YL201
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20263221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263221.